Right DHS risk assessment addresses the question: “Has the possibility of a DHS (drug hypersensitivity syndrome, either IgE–mediated (immediate) or non-IgE-mediated (delayed), i.e., ADR Type B) that could occur during the study been addressed appropriately?” [6, 7, 8]. This evidence concerns the gene IGHE and drug hypersensitivity syndrome.